Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Can Sanofi’s Toujeo Prickle Tresiba In India?

Executive Summary

Sanofi has launched its next generation basal insulin, Toujeo, on the Indian market at a significantly reduced per unit price point versus Novo Nordisk’s Tresiba (insulin degludec), setting the stage for an interesting market expansion battle.

Advertisement

Related Content

Biocon To Buttress India Market Glargine Supply From Malaysia Site
Can ‘Long-Term Partner’ Cipla Breathe New Life Into MannKind’s Afrezza?
Novo Nordisk’s Ultra Fast-Acting Insulin On Course To Indian Debut
Novo's Tresiba Significantly Reduces Hypoglycemia Versus Lantus In DEVOTE
India To Streamline Tiered Trial Approval Process – Will It Lift Sponsor Outlook?
Trends In Insulin Therapy Acceptance In India
The Lantus vs Tresiba show in India: Winners both?

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC100421

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel